Buy & Sell Quest Diagnostics Inc (DGX) – Quest Diagnostics Inc Price Today
Aura AI Summary
Key Stats
- $20.74BMarket Cap
- HealthSector
- -11.57%3M Drawdown
- $26.76BEnterprise Value
- 1.84%Dividend Yield
- 70 daysTypical Hold Time
Quest Diagnostics Inc (DGX) is currently valued at a market capitalization of $20.74B, with an enterprise value of $26.76B. Over the past 52 weeks, Quest Diagnostics Inc has traded between a low of $166.42 and a high of $211.91, highlighting its annual price range. Over the past three months, Quest Diagnostics Inc has recorded a drawdown of -11.57%, reflecting recent price volatility. Quest Diagnostics Inc offers a dividend yield of 1.84%, with the most recent dividend of $0.86 paid on 06 Apr 26. On average, investors hold Quest Diagnostics Inc for approximately 70 days, indicating typical investor behavior on the platform.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Most Recent News
New report details Diageo's financials, SWOT, and market position in Food & Beverages industry
ResearchAndMarkets.com released a comprehensive report on Diageo plc covering its financial performance, SWOT analysis, competitive landscape, and industry position. The report highlights Diageo's strengths like its strong brand portfolio and financi...
Lecanemab injection market to grow to $6.63B by 2030, driven by early Alzheimer's diagnosis and aging population
The global lecanemab injection market is projected to grow from $3.07 billion in 2026 to $6.63 billion by 2030, fueled by increased early-stage Alzheimer's diagnosis, FDA approvals, and expanded reimbursement policies. This growth is supported by inn...
Elon Musk's AI infrastructure shift turns massive losses into $5-6B profit potential
Elon Musk's AI venture xAI, previously incurring heavy losses, is pivoting to become highly profitable by monetizing its AI infrastructure. Instead of just using its Colossus supercomputer for internal AI training, Musk is positioning it as a cloud s...